A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare NSAI (Anastrozole or Letrozole) Plus Abemaciclib, a CDK4 and CDK6 Inhibitor, or Plus Placebo, and to Compare Fulvestrant Plus Abemaciclib or Plus Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer
Latest Information Update: 18 Oct 2024
At a glance
- Drugs Abemaciclib (Primary) ; Anastrozole; Fulvestrant; Letrozole
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms MONARCH plus
- Sponsors Eli Lilly and Company
- 05 Dec 2023 According to an Eli Lilly and Company media release, data from this study will be presented at the 2023 San Antonio Breast Cancer Symposium.
- 11 Sep 2023 Planned End Date changed from 20 Sep 2023 to 31 Dec 2024.
- 08 Aug 2022 Planned End Date changed from 28 Feb 2023 to 20 Sep 2023.